Risedronate for the Prevention of Osteoporosis in People With Spinal Cord Injury.

T

Toronto Rehabilitation Institute

Status and phase

Completed
Phase 3

Conditions

Acute Spinal Cord Injury.

Treatments

Drug: Risedronate

Study type

Interventional

Funder types

Other

Identifiers

NCT00150696
ONRO-79
TRI REB #02-040

Details and patient eligibility

About

The purpose of this study is to find out if Risedronate works to prevent osteoporosis after spinal cord injury.

Sex

All

Ages

16 to 60 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Traumatic spinal cord injury less than 100 days.
  • Must be able to swallow tablets and sit upright.

Exclusion criteria

  • Bilateral knee flexion contractures.
  • Pregnant, lactating or post-menopausal females.
  • Paget's disease, osteomalacia, steroid induced bone loss, untreated thyroid disease, iritis, uveitis, pancreatitis, gastritis, peptic ulcer or cholecystitis.
  • Treatment in the last year with calcitonin, fluoride or anabolic steroid.
  • Concurrent treatment with prednisone.

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems